Facebook Linkedin RSS Twitter Youtube
Home 2024

Hematologic diseases

ASGCT 2024: Gene Therapy Delivery and Development Dominates Opening Workshop
Drug Discovery

ASGCT 2024: Gene Therapy Delivery and Development Dominates Opening Workshop

FDA Clears Prime Medicine’s IND for First Prime Editing Therapy
Genome Editing

FDA Clears Prime Medicine’s IND for First Prime Editing Therapy

Uncovering RNA Splicing’s Cell-Specific Impact on Clonal Blood Disorders with GoT-Splice
Cancer

Uncovering RNA Splicing’s Cell-Specific Impact on Clonal Blood Disorders with GoT-Splice

ReciBioPharm Partners with GeneVentiv on AAV-based Gene Therapy for the Treatment of Hemophilia
Bioprocessing

ReciBioPharm Partners with GeneVentiv on AAV-based Gene Therapy for the Treatment of Hemophilia

Improving Flow through the Cell Therapies Bottleneck
Bioprocessing

Improving Flow through the Cell Therapies Bottleneck

Cell and Gene Therapy Manufacturing and Development Trends
Bioprocessing

Cell and Gene Therapy Manufacturing and Development Trends

One-Pot Method for Generating Orally Available Cyclic Peptide Drug Candidates
Drug Discovery

One-Pot Method for Generating Orally Available Cyclic Peptide Drug Candidates

“Transformer” Base Editor Safely and Durably Induces Fetal Hemoglobin in Human HSCs
Genome Editing

“Transformer” Base Editor Safely and Durably Induces Fetal Hemoglobin in Human HSCs

Bloodstream Infection Diagnostics Get Boost from Oxford Nanopore, Day Zero Partnership
Industry News

Bloodstream Infection Diagnostics Get Boost from Oxford Nanopore, Day Zero Partnership

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar
GEN Edge

StockWatch: For Genome Editing, Inflection Points Crowd the Calendar

123...29Page 2 of 29
Copyright © 2025 Genetic Engineering & Biotechnology News. All Rights Reserved.